TTRX

+ Watchlist + Portfolio

Turn Therapeutics Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $9.82
52-Week Range: $2.57 – $26.50
Market Cap: $289.71M
P/E (TTM): —
EPS (TTM): -0.28
Dividend Yield: —

Advanced Metrics

Price/Book: 46.54
PEG Ratio: —
Return on Equity: -686.28%
Return on Assets: -50.27%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 1.19
Debt/Equity: 8.91
Total Debt: $6.12M
Free Cash Flow: $4.17M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $288.35M

TTRX Income statement, annual periods, in USD
USD	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	—
Research & Development	$7.50K	$245.96K	—
Selling, General & Admin	$2.30M	$1.55M	—
Operating Expenses	$2.31M	$1.80M	—
Operating Income	-$2.31M	-$1.80M	—
EBITDA	-$2.26M	-$1.75M	—
Pretax Income	-$2.29M	-$1.77M	—
Net Income	-$2.29M	-$1.77M	—
Diluted EPS	-0.08	-0.06	-0.12
Diluted Shares	29.45M	29.45M	27.72M

TTRX Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q1 2026
Revenue	—	$0.00	—	—
Research & Development	—	$62.68K	—	—
Selling, General & Admin	—	$1.30M	—	—
Operating Expenses	—	$1.37M	—	—
Operating Income	—	-$1.37M	—	—
EBITDA	—	-$1.37M	—	—
Pretax Income	—	-$1.24M	—	—
Net Income	—	-$1.24M	—	—
Diluted EPS	-0.01	-0.04	-0.06	-0.03
Diluted Shares	29.45M	29.45M	29.45M	29.48M

Market Snapshot

About

Turn Therapeutics is a clinical-stage biotechnology company focused on developing therapies for age-related diseases. The company is working on treatments that target cellular senescence and tissue regeneration to address conditions associated with aging. Turn Therapeutics is advancing a pipeline of novel therapeutics based on its proprietary regenerative medicine platform.